Uncategorized Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health by Mbio2018|Published September 1, 2018 https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball= Project Number: 1R43CA228746-01A1 Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER
Published January 30, 2025 Manhattan BioSolutions Initiates NCI PIVOT Collaboration in Pediatric Cancers
Published June 1, 2018 Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University
Published May 15, 2023 Manhattan BioSolutions, Inc. Enters into License Option Agreement with Wisconsin Alumni Research Foundation (WARF) for the RNA Nuclease Technology
Published December 19, 2023 Manhattan BioSolutions Named as an Awardee of Science in the City QuickFire Challenge
